Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

To assess the effect of STII+ exenatide therapy, compared with STII only, on maintenance of glycaemic remission in newly diagnosed T2DM patients.

Why It Was Studied

Early short-term intensive insulin (STII) therapy can induce drug-free glycemic remission for up to 1 year in half of newly diagnosed type 2 diabetic mellitus (T2DM) patients.

Whether exenatide following STII therapy will induce higher long-term glycaemic remission is currently unknown.

Who Took Part

According to the abstract, 129 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

In this randomized, parallel-group, open-label, controlled trial, 129 patients (66 in STII+ exenatide group and 63 in STII only group) firstly completed 3-week STII therapy, then STII+ exenatide group was treated with exenatide for 12 weeks further.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Being open-label, the Exenatide study did not mask who received what.

Groups ran in parallel: each of the patients stayed in one arm throughout.

The methods mention a period of 12 weeks.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Remission Induction.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exenatide in 129 patients over 12 weeks.

The publication is from 2017 (Scientific reports), a journal based in England.

More context: the Exenatide compound page, all human trials.